Trials / Completed
CompletedNCT01432535
Pharmacokinetics of Peginterferon Alfa-2b in Participants With Moderate and Severe Renal Impairment (P05655)
A Single Dose Study to Assess Pharmacokinetics of SCH 54031 in Patients With Renal Impairment (P05655)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 79 Years
- Healthy volunteers
- Accepted
Summary
This study will compare the pharmacokinetics of a single dose of peginterferon alfa-2b (Sylatron®) in healthy participants to that in participants with moderate to severe impairment of kidney function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PegIFN-2b (Sylatron®) | Single 4.5 μg/kg dose |
Timeline
- Start date
- 2011-11-01
- Primary completion
- 2012-08-01
- Completion
- 2012-08-01
- First posted
- 2011-09-13
- Last updated
- 2017-04-07
- Results posted
- 2013-09-25
Source: ClinicalTrials.gov record NCT01432535. Inclusion in this directory is not an endorsement.